Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

Integrated genomic analysis identifies UBTF tandem duplications as a subtype...

Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA

Integrated genomic analysis identifies UBTF tandem duplications as a subtype-defining lesion in paediatric AML ( Dr Masayuki Umeda - St. Jude Children's Research Hospital, San Francisco, USA )

Asciminib found to be safe and effective for heavily pretreated patients with...

Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA

Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukaemia in chronic phase ( Dr Michael Mauro - Memorial Sloan Kettering Cancer Center, New York, USA )

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first...

Prof Andrew Wei - Monash University, Melbourne, Australia

Long-term OS benefit with oral azacitidine for acute myeloid leukaemia in first remission after intensive chemo ( Prof Andrew Wei - Monash University, Melbourne, Australia )

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL

Dr Ibrahim Aldoss - City of Hope, Duarte, USA

Allogeneic haematopoietic cell transplantation in adults with Ph-like ALL ( Dr Ibrahim Aldoss - City of Hope, Duarte, USA )

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center...

Azacitidine, venetoclax and gilteritinib for FLT3-mutated AML ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes...

Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston...

Ten-day decitabine with venetoclax in acute myeloid leukaemia: Updated outcomes across genomic subgroups ( Dr Abhishek Maiti - The University of Texas MD Anderson Cancer Center, Houston, USA )

Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory...

Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA

$Axicabtagene ciloleucel vs standard‑of‑care therapy for relapsed/refractory large B-cell lymphoma ( Dr Frederick Locke - Moffitt Cancer Centre, Tampa, USA )$

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free...

Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France

EURO-SKI: 46% of CML patients still in molecular recurrence- and treatment-free survival 3 years after TKIs ( Prof Francois-Xavier Mahon - University of Bordeaux, Bordeaux, France )

Real world data supports ciltacabtagene autoleucel as effective option for...

Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca...

Real world data supports ciltacabtagene autoleucel as effective option for triple-class exposed r/r MM ( Dr Maria-Victoria Mateos - University Hospital of Salamanca-IBSAL, Salamanca, Spain )

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared...

Dr Martin Kaiser - The Institute of Cancer Research, London UK

Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM ( Dr Martin Kaiser - The Institute of Cancer Research, London UK )

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted...

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Monoclonal antibody-based quadruplet therapy, AHCT and MRD response-adapted consolidation therapy gives highest rate of MRD negativity in NDMM ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

Latest in combination therapy for NDMM patients

Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA

Latest in combination therapy for NDMM patients ( Prof Luciano Costa - University of Alabama at Birmingham, Birmingham, USA )

More from ecancer